GSK will split into two new companies in 2022, they are GSK and Haleon. So what does this spin-off mean for Malaysia and the healthcare industry? Philip See speaks to Dr. Jonathan Pan, Vice President and GM of Malaysia and Brunei at GSK about their top-selling drugs, their role in the Covid-19 pandemic, and can Malaysia be a vaccine manufacturing hub?

Pos Malaysia: A Turnaround, Or A Good Six Months?
22:47

Is ADFIM Doing Development, Or Just Lending?
22:35

Aging Nation: Turning Demographic Shifts into Opportunity
21:09